926223-12-3

Basic information

• Product Name: 3',4'-Dichloro-biphenyl-4-aMine
• Synonyms: 3',4'-Dichloro-biphenyl-4-aMine
• CAS NO: 926223-12-3
• Molecular Formula: C12H9Cl2N
• Molecular Weight: 238.11256
• Mol File: 926223-12-3.mol

Chemical Properties

• Melting Point: 85.6-86.8 °C
• Boiling Point: 369.4±27.0 °C(Predicted)
• Appearance: /
• Density: 1.316±0.06 g/cm3(Predicted)
• PKA: 3.92±0.10(Predicted)
• CAS DataBase Reference: 3',4'-Dichloro-biphenyl-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3',4'-Dichloro-biphenyl-4-aMine(926223-12-3)
• EPA Substance Registry System: 3',4'-Dichloro-biphenyl-4-aMine(926223-12-3)

Safety Data

• Hazardous Substances Data: 926223-12-3(Hazardous Substances Data)

Upstream product

• 151169-75-4 3,4-dichlophenylboronic acid 
• 106-40-1 4-bromo-aniline 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 

Downstream Products

• 1221971-32-9 C₂₂H₁₆Cl₂N₂O₅S 
• 1221971-34-1 C₂₂H₁₆Cl₂N₂O₅S 
• 1221971-36-3 C₂₂H₁₆Cl₂N₂O₄S 
• 1221971-47-6 N-(3',4'-dichlorobiphenyl-4-yl)-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide 
• 1221971-39-6 C₂₁H₁₄Cl₂N₂O₄S 
• 1221971-38-5 C₂₁H₁₆Cl₂N₂O₄S 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

I -PrI acceleration of Negishi cross-coupling reactions

(Figure presented) The Negishi cross-coupling of arylzinc reagents with various bromoanilines is accelerated by the presence of i-PrI (1 equiv) and furnished the expected biaryls within 5-12 min reaction time at 25 °C. Arylzinc reagents can also be cross-coupled under these conditions with a range of aryl bromides bearing an enolizable ester or acidic benzylic protons.